December 20, 2024

Riluzole Shows Promise in Reversing Cognitive Decline from Radiation Therapy

Boosting brain-derived neurotrophic factor (BDNF) with riluzole may mitigate cognitive dysfunction from radiation therapy.

Conexiant

December 19, 2024

Primary Analysis of ZUMA-2: Treatment of BTK Inhibitor–Naive Relapsed/Refractory Mantle Cell Lymphoma

A primary analysis of ZUMA-2, reported at the 2024 American Society of Hematology (ASH) Annual Meeting & Exposition, evaluated brexucabtagene autoleucel in patients with Bruton’s tyrosine kinase (...

The ASCO Post

December 19, 2024

FDA Approves Ensartinib for ALK- Positive Locally Advanced or Metastatic NSCLC

The U.S. Food and Drug Administration (FDA) recently approved the anaplastic lymphoma kinase (ALK) inhibitor ensartinib (Ensacove) for adults with ALK-positive locally advanced or metastatic non–small...

The ASCO Post

December 18, 2024

Darzalex May Delay Myeloma in High-Risk Patients

For the first time, we have a treatment option that can significantly delay or prevent the progression to active disease."

Reuters

December 18, 2024

CAR T-Cell Therapy for Relapsed/Refractory Mantle Cell Lymphoma: ZUMA-2

Long-term follow-up of patients in ZUMA-2 cohorts 1 and 2 with relapsed/refractory mantle cell lymphoma who received brexucabtagene autoleucel and who were alive after 5 years were reported at the 202...

The ASCO Post

December 18, 2024

Physicians With Kids Face Large Pay Gaps

Physician compensation remains a central concern in health care, influenced by educational debt, specialty-specific variations, and evolving employer policies.

Conexiant

December 16, 2024

FDA Approves Unloxcyt for Skin Cancer

FDA approves Unloxcyt, a new drug by Checkpoint Therapeutics, for the treatment of advanced and metastatic cutaneous squamous cell carcinoma, showing promising results in clinical studies.

Reuters

December 16, 2024

FDA 6-Month Drug Pipeline

A pipeline of novel drugs awaits FDA review through the first half of 2025.

Conexiant

December 13, 2024

Adjuvant Tamoxifen May Reduce Recurrence Risk for Patients With ‘Good-Risk’ DCIS Who Forgo Radiation

For patients with “good-risk” ductal carcinoma in situ (DCIS) who underwent breast-conserving surgery and did not receive radiotherapy, tamoxifen significantly decreased the risk of recurrence in the ...

The ASCO Post